Aegerion Pharmaceuticals
AEGR
AEGR was delisted on the 29th of November, 2016.
97 hedge funds and large institutions have $554M invested in Aegerion Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 26 increasing their positions, 36 reducing their positions, and 21 closing their positions.
92% more call options, than puts
Call options by funds: $14.4M | Put options by funds: $7.51M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
10% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 21
2% less funds holding
Funds holding: 99 → 97 (-2)
28% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 36
36% less capital invested
Capital invested by funds: $865M → $554M (-$311M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NTC
North Tide Capital
Boston,
Massachusetts
|
+$15.2M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$13M |
| 3 |
Millennium Management
New York
|
+$8.79M |
| 4 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$8.64M |
| 5 |
Morgan Stanley
New York
|
+$8.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
-$60.8M |
| 2 |
State Street
Boston,
Massachusetts
|
-$33.1M |
| 3 |
JP Morgan Chase
New York
|
-$12M |
| 4 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
-$10.4M |
| 5 |
PA
Perceptive Advisors
New York
|
-$9.97M |
AEGR Hedge Fund Activity: Q2 2015 in Review
97 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q2 2015, worth a combined $554M — down 36% from $865M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of AEGR and 19 opened new positions — a net loss of 2 holders — while 36 trimmed existing stakes and 26 added.
The largest buyer was North Tide Capital, adding an estimated $15.2M. The largest seller was Westfield Capital Management, exiting entirely with an estimated $60.8M sold.
- 97 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q2 2015, down from 99 in Q1 2015.
- Funds reported $554M of Aegerion Pharmaceuticals stock for Q2 2015, down 36% quarter-over-quarter.
- 19 funds opened new Aegerion Pharmaceuticals positions in Q2 2015 and 21 closed out, a net change of -2 holders.
- The largest Aegerion Pharmaceuticals buyer in Q2 2015 was North Tide Capital, an estimated $15.2M added.
- The largest Aegerion Pharmaceuticals seller in Q2 2015 was Westfield Capital Management, an estimated $60.8M sold.
Based on aggregated 13F filings for Q2 2015.